✦ LIBER ✦

An open trial of ondansetron (GR38032F) in the treatment of acute schizophrenia

✍ Scribed by Williams, P.

Book ID: 122885856
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 74 KB
Volume: 3
Category: Article
ISSN: 0920-9964
DOI: 10.1016/0920-9964(90)90127-S

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral ondansetron (GR 38032F) for the con

Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient

✍ Elisabetta Campora; Cristina Oliva; Serafina Mammoliti; Gian Luigi Cetto; Vinici 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 345 KB

The effects of ondansetron (GR38032F) in

The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam

✍ Brenda Costall; Brian J. Jones; M. Elizabeth Kelly; Robert J. Naylor; Nigel R. O 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 871 KB

Effects of the 5-HT3 antagonist GR38032F

Effects of the 5-HT3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats

✍ Andrew J. Goudie; Michael J. Leathley 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 640 KB

Ondansetron in treatment of schizophreni

Ondansetron in treatment of schizophrenia

✍ White, Alfred; Corn, TimothyH.; Feetham, Celia; Faulconbridge, Caroline 📂 Article 📅 1991 🏛 The Lancet 🌐 English ⚖ 172 KB

An open trial of adjunctive sertraline i

An open trial of adjunctive sertraline in the treatment of chronic schizophrenia

✍ J. H. Thakore; C. Berti; T. G. Dinan 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB

GR38032F, a 5HT3receptor antagonist, in

GR38032F, a 5HT3receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting

✍ Michel Marty; Jean P. Droz; Pierre Pouillart; Bernard Paule; Nils Brion; Jacques 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 330 KB

A total of 28 patients receiving cancer chemotherapy with cisplatin-containing regimens (70-120 mg/ m 2) participated in an evaluation of the efficacy and safety of GR38032F for the prevention of acute nausea and vomiting. GR38032F, a 5HT3 receptor antagonist, was given 30 min prior to cisplatin as